iCAD (NASDAQ:ICAD) Cut to Sell at StockNews.com

StockNews.com lowered shares of iCAD (NASDAQ:ICAD) from a hold rating to a sell rating in a research report sent to investors on Wednesday morning.

iCAD Stock Down 8.1 %

ICAD stock opened at $1.64 on Wednesday. The stock has a market cap of $43.53 million, a PE ratio of -12.62 and a beta of 1.47. The firm’s 50-day simple moving average is $1.71 and its 200 day simple moving average is $1.54. iCAD has a fifty-two week low of $1.18 and a fifty-two week high of $2.65.

iCAD (NASDAQ:ICAD) last issued its quarterly earnings data on Tuesday, August 13th. The technology company reported ($0.07) earnings per share for the quarter. iCAD had a negative net margin of 17.81% and a negative return on equity of 15.30%. The business had revenue of $5.03 million for the quarter.

Hedge Funds Weigh In On iCAD

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC raised its stake in iCAD by 55.6% in the 1st quarter. Virtu Financial LLC now owns 21,286 shares of the technology company’s stock valued at $34,000 after acquiring an additional 7,604 shares during the period. Perritt Capital Management Inc. increased its holdings in iCAD by 7.5% in the first quarter. Perritt Capital Management Inc. now owns 139,983 shares of the technology company’s stock worth $225,000 after purchasing an additional 9,717 shares in the last quarter. Perritt Capital Management Inc increased its holdings in shares of iCAD by 14.2% during the second quarter. Perritt Capital Management Inc now owns 159,900 shares of the technology company’s stock valued at $208,000 after acquiring an additional 19,917 shares in the last quarter. First Eagle Investment Management LLC boosted its position in shares of iCAD by 3.2% during the first quarter. First Eagle Investment Management LLC now owns 701,525 shares of the technology company’s stock valued at $1,129,000 after buying an additional 22,000 shares during the last quarter. Finally, Essex LLC purchased a new position in iCAD in the third quarter worth $216,000. 24.61% of the stock is currently owned by institutional investors and hedge funds.

iCAD Company Profile

iCAD, Inc engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis.